Francisco Chacón-Lozsán: Cytokine Storm Is Not Just Inflammation, It Is Organ Failure in Motion
Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared on LinkedIn about a recent article by Raffaele Merola et al, published in Journal of Intensive Medicine:
” ‘Cytokine storm’ is not just inflammation, it is organ failure in motion.
A new review reframes ARDS beyond lung mechanics:
- ARDS is not only a respiratory disease
- It is a systemic immune catastrophe
What really happens in ARDS?
- Dysregulated immune activation leading to excess cytokine release
- Breakdown of the alveolar – capillary barrier
- Spillover into systemic circulation
The lung becomes the source and amplifier of systemic inflammation
Why patients die is NOT hypoxemia alone
The real driver:
Multiorgan dysfunction syndrome (MODS)
Cytokines don’t stay in the lungs:
- Brain leads to BBB disruption and neuroinflammation
- Heart leads to decreased contractility and arrhythmias
- Bone marrow leads to cytopenias
- Kidney leads to AKI, microvascular ischemia
- Liver leads to coagulopathy, DIC
ARDS becomes a whole-body disease
Not all ARDS is the same
Two key phenotypes:
Hyperinflammatory
- High IL-6, IL-8, TNF
- More shock, higher mortality
- Worse ventilator outcomes
Hypoinflammatory
- Lower cytokines
- Better outcomes
Same syndrome. Different biology. Different response to therapy.
Therapy: still behind the biology
- Lung – protective ventilation leads to cornerstone
- Corticosteroids leads to evidence-supported
- Cytokine removal, biologics, MSCs leads to promising but inconsistent
The problem: we treat ARDS as one diseas
The future is precision critical care
We should move:
From:
- ‘All ARDS patients get the same protocol’
To:
- Biomarker-guided therapy
- Subphenotype – driven interventions
- Timing-based immunomodulation
Clinical takeaway
If we don’t identify who is in a cytokine storm, we will continue to dilute effective therapies in heterogeneous populations.
ARDS is not failing because treatments don’t work.
It’s failing because we treat the wrong patients, at the wrong time, with the wrong strategy.”
Title: Cytokine storm in acute respiratory distress syndrome
Authors: Raffaele Merola, Patricia R.M. Rocco, Vito Marco Ranieri, Denise Battaglini
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12
-
Jun 24, 2026, 13:32Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care